PARI Pharma GmbH
Clinical Trials
22
Trial Phases
3 Phases
Drug Approvals
6
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT01955980
- Locations
- 🇩🇪
University Göttingen, Göttingen, Germany
🇩🇪UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz, Mainz, Germany
🇩🇪University Munich, Munich, Germany
Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Vantobra (tobramycin)
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 72
- Registration Number
- NCT01953367
- Locations
- 🇩🇪
Inamed GmbH, Gauting, Germany
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 14
- Registration Number
- NCT01946711
- Locations
- 🇩🇪
University Göttingen, Göttingen, Germany
🇩🇪UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz, Mainz, Germany
🇩🇪University LMU Munich, Munich, Germany
Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)
- Conditions
- Bronchiolitis Obliterans
- Interventions
- Drug: Inhalation
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 14
- Registration Number
- NCT01439958
- Locations
- 🇩🇪
PARI Pharma GmbH, Graefelfing, Germany
L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients
- Conditions
- Bronchiolitis Obliterans
- Interventions
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 130
- Registration Number
- NCT01334892
- Locations
- 🇩🇪
PARI Pharma GmbH, Graefelfing, Germany
News
Savara's Inhaled Molgramostim Shows 9.8% Lung Function Improvement in Phase 3 Autoimmune PAP Trial
Savara's Phase 3 IMPALA-2 trial demonstrated that inhaled molgramostim significantly improved lung function by 9.8% at 24 weeks compared to 3.8% with placebo in autoimmune pulmonary alveolar proteinosis patients.